Literature DB >> 10807072

Alpha1-antitrypsin deficiency and inflammatory bowel diseases.

P Yang1, W J Tremaine, R L Meyer, U B Prakash.   

Abstract

OBJECTIVE: To evaluate a possible etiologic role of alpha1-antitrypsin deficiency (alpha1AD), most frequently caused by a Z allele mutation, in ulcerative colitis (UC) and Crohn disease (CD). PATIENTS AND METHODS: This retrospective study included 10 patients diagnosed with and/or treated for inflammatory bowel disease (IBD) between 1976 and 1997 and identified from the Mayo Clinic Medical Index System. All 10 patients had either alpha1AD and CD or alpha1AD and UC. The alpha1-antitrypsin (alpha1AT) types and levels were determined with isoelectric focusing testing. The allele types, representing genotypes, were designated PiZZ (or ZZ) for homozygotes and PiMZ (or MZ) for heterozygotes.
RESULTS: Seven patients had UC: 4 were genotype ZZ and 3 MZ. Four of these 7 patients had emphysema, 2 had asthma, and 1 had chronic bronchitis. Five were cigarette smokers, but only 1 had smoked coincident with activity of her UC. Two of the UC patients never smoked, and 1 of these 2 had asthma. Three of the 10 patients had CD, 2 genotype ZZ and 1 MZ. Two of the 3 patients were long-term cigarette smokers, and both had emphysema. Nine of the 10 patients with UC and alpha1AD required surgery.
CONCLUSIONS: The need for surgery in patients with UC and alpha1-AD may point to a unique phenotypic subgroup of patients with alpha1AD and severe UC. Further studies are required to substantiate the etiologic role of alpha1AD in IBD. Our observations, if confirmed by future studies, suggest that in patients with both IBD and chronic obstructive pulmonary disease, alpha1AD testing should be considered.

Entities:  

Mesh:

Year:  2000        PMID: 10807072

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  10 in total

1.  Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD.

Authors:  Anders Ekbom; Lena Brandt; Fredrik Granath; Claes-Göran Löfdahl; Arne Egesten
Journal:  Lung       Date:  2008-03-11       Impact factor: 2.584

2.  Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis.

Authors:  Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 3.  Neutrophils and inflammatory metabolism in antimicrobial functions of the mucosa.

Authors:  Eric L Campbell; Sean P Colgan
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

4.  α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection.

Authors:  Galit Shahaf; Hadas Moser; Eyal Ozeri; Mark Mizrahi; Avishag Abecassis; Eli C Lewis
Journal:  Mol Med       Date:  2011-06-09       Impact factor: 6.354

5.  Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival.

Authors:  Yan Li; Michael J Krowka; Yingwei Qi; Jerry A Katzmann; Yong Song; Yafei Li; Sumithra J Mandrekar; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice.

Authors:  Sandhya Subramanian; Galit Shahaf; Eyal Ozeri; Lisa M Miller; Arthur A Vandenbark; Eli C Lewis; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-03-25       Impact factor: 3.584

Review 7.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

Review 8.  Protease inhibition as new therapeutic strategy for GI diseases.

Authors:  Nathalie Vergnolle
Journal:  Gut       Date:  2016-04-12       Impact factor: 23.059

9.  Point Mutation of a Non-Elastase-Binding Site in Human α1-Antitrypsin Alters Its Anti-Inflammatory Properties.

Authors:  Yotam Lior; Mariana Zaretsky; David E Ochayon; Diana Lotysh; Boris M Baranovski; Ronen Schuster; Ofer Guttman; Amir Aharoni; Eli C Lewis
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561

10.  Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US.

Authors:  Robert Sandhaus; Charlie Strange; Glenda Stone; M Chris Runken; Christopher M Blanchette; Reuben Howden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.